Valeant Pharmaceuticals International, Inc. (VRX)
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
Valeant Pharmaceuticals International, Inc. (VRX)‘s Financial Overview
Valeant Pharmaceuticals International, Inc. (VRX) surged 0.78% yesterday to close its trading session at $15.47. The company has 1 year Price Target of $16.75. The stock touched its 52-Week High on Obsolete and 52-Week Low on Obsolete. The stock traded with the volume of 6.29 Million shares yesterday. The firm shows the market capitalization of $5.6 Billion.
Valeant Pharmaceuticals International, Inc. (VRX) reported its last quarterly earnings on 12/30/2017 where the firm reported its Actual EPS of $0.98/share. The difference between the actual and expected EPS is $0.01 a share with a surprise factor of 1%.
The firm is trading with SMA20 of -2.26 Percent, SMA50 of SMA50 Percent and SMA200 of -5.53 percent. Valeant Pharmaceuticals International, Inc. has P/S value of 0.64 while its P/B value stands at 0.93. Similarly, the company has Return on Assets of 6 percent, Return on Equity of 50.6 percent and Return on Investment of 9.8 Percent. The company shows Gross Margin and Operating Margin of 70.8 percent and -0.2 percent respectively.
The Stock currently has Analyst’ mean Recommendation of 3 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.
The 18 analysts offering 12-month price forecasts for Valeant Pharmaceuticals International Inc have a median target of 16.50, with a high estimate of 35.00 and a low estimate of 8.00. The median estimate represents a +6.66% increase from the last price of 15.47.
Zion Oil & Gas, Inc. (ZN)
ZION OIL & GAS, INC. was founded for the purpose of exploring for oil and gas in Israel and reaching production levels that would help Israel become an energy independent country. Zion Oil & Gas, a Delaware corporation, explores for oil and gas in Israel in areas located on-shore between Haifa and Tel Aviv. It currently holds two petroleum exploration licenses, the Joseph and the Asher-Menashe Licenses, between Netanya on the south and Haifa on the north. From its inception, the calling of Zion Oil & Gas has been to assist Israel in the restoration of the Land by finding and producing oil and gas helping to make Israel politically and economically independent.
Zion Oil & Gas, Inc. (ZN)’s Financial Outlook
There is no forecast data available.
According to Zacks Investment Research, Zion Oil & Gas, Inc. has a Consensus Recommendation of NA. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).
The Stock declined-15.57% and closed its last trading session at $3.96. The company has the market capitalization of $209.09 Million. The firm touched its 52-Week high on Obsolete and 52-Week low on Obsolete. The company has volume of 6.26 Million shares. The company has a total of 52.8 Million shares outstanding.
The company has YTD performance of 83.33 percent. Beta for Zion Oil & Gas, Inc. stands at -0.03 while its ATR (average true range) is 0.52. The company has Weekly Volatility of 19.59%% and Monthly Volatility of 10.62%.
Zion Oil & Gas, Inc. has distance from 20-day Simple Moving Average (SMA20) of -15.98%, Distance from 50-Day Simple Moving Average of SMA50 percent and Distance from 200-Day Simple Moving Average of 26.45%.